IGC Pharma, Inc. financial data

Symbol
IGC on NYSE
Location
Potomac, MD
Fiscal year end
31 March
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 124 % -25.6%
Quick Ratio 58.9 % -13.1%
Debt-to-equity 32.7 % -1.42%
Return On Assets -72.6 % +39.2%
Operating Margin -732 % +7.15%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 92.9M shares +19.9%
Common Stock, Shares, Outstanding 92M shares +20%
Entity Public Float 29.7M USD +42.3%
Weighted Average Number of Shares Outstanding, Basic 90.5M shares +19%
Weighted Average Number of Shares Outstanding, Diluted 90.5M shares +19%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.11M USD -6.51%
Cost of Revenue 595K USD +14.9%
Research and Development Expense 4.29M USD +20.3%
Operating Income (Loss) -8.09M USD +13.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -6.45M USD +48.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -6.45M USD +48.7%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.11M USD -28.5%
Marketable Securities, Current 154K USD
Accounts Receivable, after Allowance for Credit Loss, Current 41K USD -6.82%
Inventory, Net 658K USD -56.4%
Other Assets, Current 130K USD -34.3%
Assets, Current 2M USD -52.8%
Property, Plant and Equipment, Net 2.18M USD -37.3%
Operating Lease, Right-of-Use Asset 13K USD -91.9%
Intangible Assets, Net (Excluding Goodwill) 4.88M USD +171%
Other Assets, Noncurrent 672K USD -2.18%
Assets 9.74M USD -6.04%
Accounts Payable, Current 628K USD -18.2%
Employee-related Liabilities, Current 398K USD -61.5%
Accrued Liabilities, Current 886K USD -56.4%
Liabilities, Current 1.51M USD -46%
Operating Lease, Liability, Noncurrent 5K USD -85.7%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 1.65M USD -44.8%
Common Stocks, Including Additional Paid in Capital 136M USD +5.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.85M USD -41.1%
Retained Earnings (Accumulated Deficit) -123M USD -4.3%
Stockholders' Equity Attributable to Parent 8.09M USD +9.69%
Liabilities and Equity 9.74M USD -6.04%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.41M USD +19.7%
Net Cash Provided by (Used in) Financing Activities 851K USD -66.1%
Net Cash Provided by (Used in) Investing Activities 580K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 92M shares +20%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 49K USD -92.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.11M USD -28.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1K USD 0%
Deferred Tax Assets, Valuation Allowance 19.1M USD +27.7%
Deferred Tax Assets, Gross 19.1M USD +27.7%
Operating Lease, Liability 103K USD -50.5%
Depreciation 512K USD -10.6%
Payments to Acquire Property, Plant, and Equipment 8K USD -78.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.48M USD +48.4%
Lessee, Operating Lease, Liability, to be Paid 340K USD -26.7%
Property, Plant and Equipment, Gross 3.89M USD -35.9%
Operating Lease, Liability, Current 9K USD -93.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10K USD -88.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 96K USD -27.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD -72.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 14K USD -30%
Depreciation, Depletion and Amortization 141K USD -13%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 452K USD +12.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%